Show simple item record

dc.contributor.authorMyint, H Y
dc.contributor.authorAshley, E A
dc.contributor.authorDay, N P J
dc.contributor.authorNosten, F
dc.contributor.authorWhite, N J
dc.date.accessioned2009-03-05T15:39:25Z
dc.date.available2009-03-05T15:39:25Z
dc.date.issued2007-09
dc.date.submitted2009-03-04
dc.identifier.citationEfficacy and safety of dihydroartemisinin-piperaquine. 2007, 101 (9):858-66 Trans. R. Soc. Trop. Med. Hyg.en
dc.identifier.issn0035-9203
dc.identifier.pmid17659311
dc.identifier.doi10.1016/j.trstmh.2007.05.018
dc.identifier.urihttp://hdl.handle.net/10144/52374
dc.description.abstractDihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. Efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria. More than 2600 patients have been treated with this combination in prospective studies, mainly in Southeast Asia. Tolerability was uniformly good, and no serious adverse effects have been identified. The dosing regimen has been simplified from four doses to once daily over 3 days. More information on efficacy in Africa, and more pharmacokinetic and efficacy data in children are needed.
dc.description.sponsorshipEpicentreen
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/journal/00359203en
dc.rightsPublished by Elsevier Archived on this site with the kind permission of Elsevier Ltd. ([url]http://www.sciencedirect.com/science/journal/00359203[/url]) and the Royal Society of Tropical Medicine and Hygiene ([url]http://www.rstmh.org/transactions.asp[/url])en
dc.subject.meshAntimalarialsen
dc.subject.meshArtemisininsen
dc.subject.meshAsia, Southeasternen
dc.subject.meshDrug Combinationsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMalaria, Falciparumen
dc.subject.meshMaleen
dc.subject.meshQuinolinesen
dc.subject.meshSesquiterpenesen
dc.subject.meshTreatment Outcomeen
dc.titleEfficacy and safety of dihydroartemisinin-piperaquine.en
dc.typeArticleen
dc.contributor.departmentFaculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand.en
dc.identifier.journalTransactions of the Royal Society of Tropical Medicine and Hygieneen
refterms.dateFOA2019-03-04T12:17:33Z
html.description.abstractDihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. Efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria. More than 2600 patients have been treated with this combination in prospective studies, mainly in Southeast Asia. Tolerability was uniformly good, and no serious adverse effects have been identified. The dosing regimen has been simplified from four doses to once daily over 3 days. More information on efficacy in Africa, and more pharmacokinetic and efficacy data in children are needed.


Files in this item

Thumbnail
Name:
409_piperaquine.pdf
Size:
276.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record